NYSE:ALC - Alcon Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $64.20
  • Forecasted Upside: 0.64 %
  • Number of Analysts: 18
  • Breakdown:
  • 4 Sell Ratings
  • 6 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$63.79
▲ +0.61 (0.97%)
1 month | 3 months | 12 months
Get New Alcon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$64.20
▲ +0.64% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Alcon in the last 3 months. The average price target is $64.20, with a high forecast of $78.00 and a low forecast of $50.00. The average price target represents a 0.64% upside from the last price of $63.79.
Hold
The current consensus among 18 polled investment analysts is to hold stock in Alcon. This rating has held steady since June 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
6/7/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 1 sell ratings
9/5/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 2 sell ratings
12/4/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 3 sell ratings
3/3/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 4 sell ratings
6/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 4 sell ratings
8/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 4 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 4 sell ratings
11/28/2020

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 4 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/19/2020Berenberg BankReiterated RatingBuyN/A
i
11/16/2020JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
11/13/2020Credit Suisse GroupBoost Price TargetOutperform$71.00 ➝ $76.00N/A
i
Rating by Matt Miksic at Credit Suisse Group AG
11/12/2020Jefferies Financial GroupBoost Price TargetBuy$71.00 ➝ $78.00N/A
i
11/12/2020Morgan StanleyBoost Price TargetOverweight$66.00 ➝ $73.00N/A
i
11/12/2020SVB LeerinkBoost Price TargetMarket Perform$61.00 ➝ $67.00N/A
i
11/12/2020GuggenheimDowngradeBuy ➝ NeutralN/A
i
Rating by Christopher Pasquale at Guggenheim
9/1/2020Berenberg BankReiterated RatingBuyN/A
i
8/27/2020Societe GeneraleDowngradeHold ➝ SellN/A
i
Rating by Delphine Le Louet at Societe Generale
8/20/2020SVB LeerinkBoost Price TargetMarket Perform$57.00 ➝ $61.00N/A
i
8/17/2020Credit Suisse GroupReiterated RatingBuy$63.00N/A
i
Rating by Matt Miksic at Credit Suisse Group AG
7/6/2020KeyCorpInitiated CoverageSector WeightN/A
i
7/6/2020CitigroupDowngradeNeutral ➝ Sell$55.00N/A
i
6/16/2020GuggenheimUpgradeNeutral ➝ Buy$68.00N/A
i
5/21/2020JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
5/14/2020Wells Fargo & CompanyBoost Price TargetOverweight$58.00 ➝ $62.00N/A
i
5/14/2020SVB LeerinkBoost Price TargetMarket Perform$56.00 ➝ $57.00N/A
i
5/14/2020CitigroupBoost Price TargetNeutral$54.00 ➝ $55.00N/A
i
5/14/2020StephensUpgradeEqual Weight ➝ OverweightN/A
i
4/20/2020BTIG ResearchReiterated RatingHoldN/A
i
4/9/2020Wells Fargo & CompanyLower Price TargetOverweight$70.00 ➝ $58.00N/A
i
4/8/2020SVB LeerinkLower Price TargetMarket Perform$62.00 ➝ $56.00N/A
i
4/8/2020Robert W. BairdDowngradeOutperform ➝ Neutral$69.00 ➝ $58.00N/A
i
3/27/2020CitigroupLower Price TargetNeutral$63.00 ➝ $54.00N/A
i
3/27/2020Morgan StanleyLower Price TargetOverweight$70.00 ➝ $66.00N/A
i
3/27/2020Kepler Capital MarketsReiterated RatingSellN/A
i
3/26/2020ArgusUpgradeHold ➝ Buy$55.00N/A
i
3/24/2020Societe GeneraleUpgradeSell ➝ HoldN/A
i
3/23/2020StephensLower Price TargetEqual Weight$68.00 ➝ $50.00N/A
i
3/13/2020UBS GroupUpgradeNeutral ➝ BuyN/A
i
3/12/2020Berenberg BankReiterated RatingBuyN/A
i
3/11/2020SVB LeerinkLower Price TargetMarket Perform$68.00 ➝ $62.00N/A
i
3/10/2020Kepler Capital MarketsReiterated RatingSellN/A
i
3/6/2020Credit Suisse GroupReiterated RatingBuy$69.00N/A
i
Rating by Matt Miksic at Credit Suisse Group AG
3/4/2020CitigroupInitiated CoverageNeutral$63.00N/A
i
3/4/2020Redburn PartnersDowngradeNeutral ➝ SellN/A
i
2/27/2020Credit Suisse GroupBoost Price TargetOutperform$68.00 ➝ $72.00N/A
i
2/27/2020StephensBoost Price TargetEqual Weight$62.00 ➝ $68.00N/A
i
2/27/2020Kepler Capital MarketsReiterated RatingSellN/A
i
2/26/2020Berenberg BankUpgradeHold ➝ BuyN/A
i
1/8/2020ArgusInitiated CoverageHoldN/A
i
12/17/2019Morgan StanleyLower Price TargetOverweight$71.00 ➝ $70.00N/A
i
11/24/2019BTIG ResearchReiterated RatingHoldN/A
i
Rating by Ryan Zimmerman at BTIG Research
11/20/2019Berenberg BankReiterated RatingHoldN/A
i
11/11/2019Redburn PartnersUpgradeSell ➝ NeutralN/A
i
10/28/2019StephensInitiated CoverageEqual ➝ Equal WeightN/A
i
8/26/2019Credit Suisse GroupBoost Price TargetOutperform$68.00 ➝ $73.00N/A
i
Rating by Matt Miksic at Credit Suisse Group AG
8/21/2019BTIG ResearchReiterated RatingHoldN/A
i
Rating by Ryan Zimmerman at BTIG Research
8/21/2019Bank of AmericaReiterated RatingNeutral$62.00 ➝ $65.00N/A
i
8/16/2019Credit Suisse GroupSet Price TargetBuy$68.00N/A
i
Rating by Matt Miksic at Credit Suisse Group AG
7/16/2019Morgan StanleyBoost Price TargetOverweight$65.00 ➝ $71.00N/A
i
6/24/2019SVB LeerinkInitiated CoverageMarket Perform$62.00N/A
i
Rating by R. Newitter at SVB Leerink LLC
6/14/2019BTIG ResearchInitiated CoverageNeutral ➝ NeutralN/A
i
6/3/2019Credit Suisse GroupReiterated RatingOutperformN/A
i
5/10/2019Robert W. BairdInitiated CoverageOutperform$69.00 ➝ $68.00N/A
i
5/9/2019OppenheimerInitiated CoverageOutperform$69.00N/A
i
5/2/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$66.00N/A
i
4/18/2019BMO Capital MarketsInitiated CoverageMarket Perform ➝ Market PerformN/A
i
4/15/2019Jefferies Financial GroupInitiated CoverageBuyN/A
i
4/10/2019Societe GeneraleInitiated CoverageBuy ➝ BuyN/A
i
4/10/2019Berenberg BankInitiated CoverageHoldN/A
i
4/10/2019Morgan StanleyInitiated CoverageOverweight$65.00N/A
i
4/10/2019JPMorgan Chase & Co.Initiated CoverageNeutralN/A
i
4/10/2019UBS GroupInitiated CoverageNeutralN/A
i
4/9/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$66.00N/A
i
4/8/2019Cleveland ResearchInitiated CoverageNeutralN/A
i
(Data available from 11/29/2015 forward)
Alcon logo
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients. It operates through two segments, Surgical and Vision Care. The Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures, such as cataracts, vitreoretinal, refractive laser, and glaucoma surgery. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR ophthalmic microscope, verion imaged guided system, and ORA System for intra-operative measurements and guidance; vitreoretinal products comprising constellation vision system, grieshaber DSP and MIVS instrumentation, ultravit high speed vitrectomy probes, purepoint laser, and NGENUITY 3D visualization system; refractive surgery products, including WaveLight lasers and diagnostics used for LASIK; and glaucoma product, such as EX-PRESS glaucoma filtration device, as well as AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. The Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers under the TOTAL, PRECISION, Dailies, Air Optix, Systane, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Read More

Today's Range

Now: $63.79
$63.16
$63.95

50 Day Range

MA: $61.97
$56.84
$66.11

52 Week Range

Now: $63.79
$39.37
$68.11

Volume

199,790 shs

Average Volume

1,152,280 shs

Market Capitalization

$31.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5